Tranylcypromine isomers in the treatment of Parkinson's disease. Biochemical effects.
Isomers of the monoamine oxidase inhibitor tranylcypromine were administered separately to 15 hospitalized parkinsonian patients. The activity of the platelet enzyme, the plasma and urinary tranylcypromine, were measured. While the (+)isomer inhibited monoamine oxidase to a greater extent, both isomers increased plasma phenylethylamine. Differences between the pharmacokinetics of the two isomers were substantial, (-)tranylcypromine being excreted much faster.
D001792:Blood Platelets / Q000201:enzymology; D006801:Humans; D007700:Kinetics; D008995:Monoamine Oxidase / Q000378:metabolism; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism; D010627:Phenethylamines / Q000378:metabolism; D013237:Stereoisomerism; D014191:Tranylcypromine / Q000378:metabolism / Q000627:therapeutic use*
D010627:Phenethylamines; D014191:Tranylcypromine; D008995:Monoamine Oxidase